Equities

Chunghwa Chemical Synthesis & Biotech Co Ltd

1762:TAI

Chunghwa Chemical Synthesis & Biotech Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)42.30
  • Today's Change0.00 / 0.00%
  • Shares traded81.14k
  • 1 Year change-28.31%
  • Beta--
Data delayed at least 20 minutes, as of Sep 23 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of TWD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments270301195
Total Receivables, Net257312396
Total Inventory1,211820754
Prepaid expenses501612
Other current assets, total------
Total current assets1,7881,4491,357
Property, plant & equipment, net2,2921,9641,868
Goodwill, net------
Intangibles, net5.567.531.80
Long term investments1,0051,0091,070
Note receivable - long term------
Other long term assets6111559
Total assets5,1724,5644,381
LIABILITIES
Accounts payable10414479
Accrued expenses122178144
Notes payable/short-term debt500100150
Current portion long-term debt/capital leases3.362.541.32
Other current liabilities, total101189261
Total current liabilities831614635
Total long term debt704501601
Total debt1,208603752
Deferred income tax259256250
Minority interest00.190.19
Other liabilities, total27----
Total liabilities1,8211,3711,487
SHAREHOLDERS EQUITY
Common stock776776776
Additional paid-in capital335334334
Retained earnings (accumulated deficit)2,2962,1291,744
Treasury stock - common------
Unrealized gain (loss)(50)(45)44
Other equity, total(5.93)(1.49)(4.03)
Total equity3,3503,1932,894
Total liabilities & shareholders' equity5,1724,5644,381
Total common shares outstanding787878
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.